General Announcement::Press Release: iX Biopharma Successfully Completes Phase 1 Sublingual Dexmedetomidine Clinical Study

Issuer & Securities

Announcement Title: General Announcement
Date &Time of Broadcast: 10-Feb-2023 07:11:28
Status: New
Announcement Sub Title: Press Release: iX Biopharma Successfully Completes Phase 1 Sublingual Dexmedetomidine Clinical Study
Announcement Reference: SG230210OTHR61VD
Submitted By (Co./ Ind. Name): Gwendolin Lee Soo Fern
Designation: Company Secretary
Description (Please provide a detailed description of the event in the box below): Please see attached.

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.

Total size =97K